NIDA Clinical Trials Network: New York Node

NIDA 临床试验网络：纽约节点

• 批准号: 10855627
• 负责人: Jennifer McNeely
• 金额: $ 286.74万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10855627
• 关键词: Academia; Accident and Emergency department; Address; Adoption; Advocacy; Alaska Native; Alcohols; American Indians; Ancillary Study; Area; Behavior Therapy; Buprenorphine; Caring; Cities; Clinic; Clinical; Clinical Management; Clinical Trials; Clinical Trials Network; Collaborations; Communities; Criminal Justice; Data Analytics; Data Science; Effectiveness; Electronic Health Record; Evidence based intervention; Funding; Future; Generations; Health; Health Personnel; Healthcare Systems; Individual; Infrastructure; Injections; Intervention; Lead; Long Island; Mainstreaming; Medical; Mental disorders; Minority; Naltrexone; National Institute of Drug Abuse; New York; Nicotine; Opioid; Patients; Pharmaceutical Preparations; Pharmacotherapy; Policies; Policy Maker; Prevention; Prevention trial; Primary Care; Provider; Public Health; Research; Research Personnel; Schedule; Science; Scientist; Services; Site; Surveys; Technology; Training; Translating; Treatment outcome; Vision; Withdrawal; Woman; Work; addiction; community organizations; digital; health care settings; health economics; implementation facilitation; implementation science; improved; innovation; medical specialties; metropolitan; novel; opioid epidemic; opioid use; opioid use disorder; pre-exposure prophylaxis; predictive modeling; primary care provider; stimulant dependence; treatment program; virtual

The New York Node (NYN) of the NIDA CTN, led by John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes, which had been part of the CTN since 2000 and 2001, respectively. This fourth competing renewal application builds on both a strong and successful infrastructure to manage clinical trials, and a track record of innovation and successful implementation of trials in mainstream healthcare settings where most SUD patients are seen. We contribute expertise in virtually all key CTN priorities outlined in RFA-DA-20-024, including: integration of SUD treatment and prevention in mainstream settings (primary care, emergency departments, criminal justice); leveraging the electronic health record to support improved and expanded care; developing medications and behavioral therapies; co-occurring medical and psychiatric disorders; women and minorities; digital and other technology-based interventions; data science including novel data analytic approaches; and implementation science, health economics, advocacy, and policy to sustain evidence-based interventions. In the new funding period, the NYN will lead or co-lead seven ambitious projects, all scheduled to begin in 2019 or 2020: CTN-0079-A1 Ancillary Study of the Adoption and Sustainability of ED-Initiated Buprenorphine; CTN-0082 Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and Community Based Organizations; CTN-0094 Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome; CTN-0096 Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives; CTN-0097 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder; CTN-0100 Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; and CTN-0101 Subthreshold Opioid Use Disorder Prevention (STOP) Trial. We will also continue to help develop new trials in CTN, including in the area of stimulant dependence, and to supply sites for CTN trials. To support this, we have built a network of collaborating researchers, providers, and policy makers from academia, community-based addiction treatment programs, large multifaceted healthcare systems, and NY City and State agencies, all in the nation’s largest and most diverse metropolitan area. We have established a track record of substantial contributions to the CTN, building on our work through deliberate, rigorous, and stepwise improvements. Our vision for the Network’s future includes work built around addressing gaps highlighted by the opioid treatment cascade, interventions for stimulant dependence, effective use of the CTN platform to enable a broad range of non-CTN studies, and a continued commitment to training a new generation of addictions clinical researchers. Further, we partner with implementation scientists, health economists, advocacy groups, and policy experts to maximize the sustainability of effective new interventions.

NIDA CTN的纽约节点（NYN）由John Rotrosen和Edward Nunes领导，代表2010年 纽约和长岛节点的合并，这两个节点自2000年和2001年以来一直是CTN的一部分， 分别这第四个竞争性续订应用程序建立在强大而成功的基础架构之上， 管理临床试验，以及创新和成功实施主流试验的跟踪记录 大多数SUD患者就诊的医疗机构。我们为几乎所有关键的CTN提供专业知识 RFA-DA-20-024中概述的优先事项，包括：将SUD治疗和预防纳入主流 设置（初级保健，急诊室，刑事司法）;利用电子健康记录， 支持改善和扩大护理;开发药物和行为疗法;共同发生的医疗 精神疾病;妇女和少数群体;数字和其他技术干预措施;数据 科学，包括新的数据分析方法;和实施科学，卫生经济学，宣传， 和政策，以维持基于证据的干预措施。在新的融资期内，NYN将牵头或共同牵头 七个雄心勃勃的项目，全部计划于2019年或2020年开始：CTN-0079-A1 ED引发的丁丙诺啡的可持续性; CTN-0082 PrEP和阿片类药物使用的实施调查 性病诊所和社区组织的相关服务; CTN-0094个人水平预测 阿片类药物使用障碍治疗结果建模; CTN-0096以文化为中心的OUD MAT 为美国服务的初级保健和成瘾治疗计划的实施促进 印第安人/阿拉斯加原住民; CTN-0097克服撤回以启动纳洛酮快速治疗（SWIFT）： 提高纳洛酮注射液治疗阿片类药物使用障碍的实际有效性; CTN-0100优化 阿片类药物使用障碍药物治疗的保留、持续时间和停药策略;以及CTN-0101 阈下阿片类药物使用障碍预防（STOP）试验。我们还将继续帮助开展新的试验， CTN，包括兴奋剂依赖领域，并为CTN试验提供场地。 为了支持这一点，我们建立了一个合作研究人员，供应商和政策制定者的网络， 学术界，以社区为基础的成瘾治疗计划，大型多方面的医疗保健系统，以及纽约 城市和国家机构，都在全国最大和最多样化的大都市区。我们建立了 对CTN的实质性贡献的跟踪记录，通过深思熟虑，严格， 逐步改善。我们对网络未来的愿景包括围绕解决差距而开展的工作 阿片类药物治疗级联、兴奋剂依赖干预、CTN的有效使用 平台，使广泛的非CTN研究，并继续致力于培训新的 一代成瘾临床研究者。此外，我们还与实施科学家、健康 经济学家、倡导团体和政策专家，以最大限度地提高有效的新干预措施的可持续性。

项目成果

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".

• DOI: 10.1186/s13722-021-00223-z
• 发表时间: 2021-03-06
• 期刊: Addiction science & clinical practice
• 影响因子: 3.7
• 作者: Shulman M;Weiss R;Rotrosen J;Novo P;Costello E;Nunes EV
• 通讯作者: Nunes EV

Computational theory-driven studies of reinforcement learning and decision-making in addiction: What have we learned?

• DOI: 10.1016/j.cobeha.2020.08.007
• 发表时间: 2021-04
• 期刊: Current opinion in behavioral sciences
• 影响因子: 5
• 作者: Gueguen MCM;Schweitzer EM;Konova AB
• 通讯作者: Konova AB

Implementation facilitation to introduce and support emergency department-initiated buprenorphine for opioid use disorder in high need, low resource settings: protocol for multi-site implementation-feasibility study.

• DOI: 10.1186/s13722-021-00224-y
• 发表时间: 2021-03-09
• 期刊: Addiction science & clinical practice
• 影响因子: 3.7
• 作者: McCormack RP;Rotrosen J;Gauthier P;D'Onofrio G;Fiellin DA;Marsch LA;Novo P;Liu D;Edelman EJ;Farkas S;Matthews AG;Mulatya C;Salazar D;Wolff J;Knight R;Goodman W;Hawk K
• 通讯作者: Hawk K

Recent and active problematic substance use among primary care patients: Results from the alcohol, smoking, and substance involvement screening test in a multisite study.

• DOI: 10.1080/08897077.2021.1901176
• 发表时间: 2021
• 期刊: SUBSTANCE ABUSE
• 影响因子: 3.5
• 作者: John, William S.;Zhu, He;Greenblatt, Lawrence H.;Wu, Li-Tzy
• 通讯作者: Wu, Li-Tzy

Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults.

• DOI: 10.1016/j.jsat.2021.108277
• 发表时间: 2021-09
• 期刊: Journal of substance abuse treatment
• 影响因子: 3.9
• 作者: Elkington KS;Nunes E;Schachar A;Ryan ME;Garcia A;Van DeVelde K;Reilly D;O'Grady M;Williams AR;Tross S;Wilson P;Cohall R;Cohall A;Wainberg M
• 通讯作者: Wainberg M